Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

Completed · Phase 2 · Has a placebo group

Conditions studied: Pseudomonas Aeruginosa Pneumonia

In brief

Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia caused by P. aeruginosa.

Key facts

Study ID
NCT03027609
Run by
Aridis Pharmaceuticals, Inc.
People needed
158
Starts
2017-03-29
Expected to finish
2019-04-25
Last updated by the study team
2022-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.